Why the study?
Does first-line chemotherapy with GnP or FOLFIRINOX result in different overall survival for recurrent pancreatic cancer compared to de novo metastatic pancreatic cancer?
Cohort (n=255)
Does first-line chemotherapy with GnP or FOLFIRINOX result in different overall survival for recurrent pancreatic cancer compared to de novo metastatic pancreatic cancer?
Answers are grounded in this paper and cite their sources.
Both FOLFIRINOX and GnP provide comparable overall survival outcomes for patients with recurrent pancreatic cancer and de novo metastatic pancreatic cancer.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
A 1987 study conducted a cohort in recurrent and de novo metastatic pancreatic cancer (n=255). recurrent pancreatic cancer (rPC) vs. de novo metastatic pancreatic cancer (mPC) was evaluated on median overall survival (OS) (p=0.02).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: